Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Amorolfine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.77 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 12/20 | 0.39 |
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | EBP | Q15125 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amorolfine SCHEMBL1934866 | 1.00 | ADORA3 (0.97) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| Amorolfine SCHEMBL5579008 | 1.00 | ADORA3 (0.97) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| Amorolfine SCHEMBL150666 | 0.99 | ADORA3 (1.00) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| Amorolfine SCHEMBL933541 | 0.99 | ADORA3 (1.00) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| Amorolfine SCHEMBL8165433 | 0.99 | ADORA3 (1.00) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| Amorolfine SCHEMBL3820874 | 0.96 | ADORA3 (0.91) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| Amorolfine SCHEMBL1649004 | 0.96 | ADORA3 (0.95) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| Amorolfine SCHEMBL23111397 | 0.89 | ADORA3 (0.81) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| SCHEMBL19823129 | 0.89 | ADORA3 (0.81) | ADORA3CHRM1DRD3KCNH2SIGMAR1 | |
| Fenpropimorph SCHEMBL3710228 | 0.88 | SIGMAR1 (0.97) | ADORA3CHRM1DRD3KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | claimed |
| CN-119587466-A | Amorolfine hydrochloride liniment and its preparing process | 江苏晨牌邦德药业有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118527207-B | Crushing device for producing and processing amorolfine hydrochloride liniment | 江苏知原药业股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | claimed |
| CN-119235756-A | Amorolfine hydrochloride emulsifiable paste and preparation method thereof | 遂成药业股份有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | claimed |
| CN-118477037-B | Amorolfine hydrochloride emulsifiable paste | 江苏福邦药业有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-118527207-A | Crushing device for producing and processing amorolfine hydrochloride liniment | 江苏知原药业股份有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-221557676-U | Medicament purification filtration equipment | 药探探(武汉)医药科技有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118477037-A | Amorolfine hydrochloride emulsifiable paste | 江苏福邦药业有限公司 | 2024-08-13 | — | — | CN | claimed |
| EP-1263426-B1 | PREPARATIONS FOR THE NON-TRAUMATIC EXCISION OF A NAIL | KRAEMER KARL (DE) | 2006-03-15 | — | — | EP | claimed |
| EP-1267932-B1 | ANTI-INFECTIVE ACTIVE SUBSTANCE COMBINATIONS AND THE USE THEREOF FOR THE TOPICAL TREATMENT OF FUNGUS DISEASES OF TOE AND FINGER NAILS | AVENTIS PHARMA GMBH (DE) | 2004-02-18 | — | — | EP | claimed |
| US-20030086881-A1 | Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-05-08 | — | — | US | claimed |
| US-20030012749-A1 | Preparations for the non-traumatic excision of a nail | KRAEMER KARL (DE) | 2003-01-16 | — | — | US | claimed |
| US-20010046478-A1 | Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-29 | — | — | US | claimed |
| US-6017920-A | Antifungal composition for external use being retentive in stratum corneum | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-01-25 | — | — | US | claimed |
| EP-0971746-A1 | SOLVENT SYSTEM FOR ENHANCED PENETRATION OF PHARMACEUTICAL COMPOUNDS | Johnson & Johnson Consumer Companies, Inc. (US) | 2000-01-19 | — | — | EP | claimed |
| WO-1998043673-A1 | SOLVENT SYSTEM FOR ENHANCED PENETRATION OF PHARMACEUTICAL COMPOUNDS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| EP-0715856-A1 | KERATIN-STORABLE ANTIFUNGAL COMPOSITION FOR EXTERNAL USE | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1996-06-12 | — | — | EP | claimed |
| EP-0389778-B1 | Nail Varnish | HOFFMANN LA ROCHE (CH) | 1994-05-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | CHRM1 533/4885DRD3 3321/4885KCNH2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.